Research Paper Volume 16, Issue 4 pp 3734—3749
Identification of hypoxic-related lncRNAs prognostic model for revealing clinical prognostic and immune infiltration characteristic of cutaneous melanoma
Figure 7. Somatic mutation landscape and drug sensitivity in CM. (A) TMB analysis. (B, C) Genetic mutation frequency in the low-risk and high-risk groups. (D) TIDE scores of CM patients in the low-risk and high-risk groups. (E–G) IPS results in the low-risk and high-risk groups. Distribution of IC50 values in the low-risk and high-risk groups for (H) dasatinib, (I) crizotinib, (J) paclitaxel, (K) imatinib, and (L) cyclopamine.